CytoDyn CYDY
OTC CYDY
$0.20 +0.00 (+0.00%)
At close: Oct 15, 2026 · 4:00 PM EDT

CytoDyn (CYDY) Receivables - Other (2012)

Updated

CytoDyn (CYDY) recorded Receivables - Other of $250,000 in fiscal Q1 2013 (quarter ended Aug 31, 2012).

Analysis

CytoDyn (CYDY) Receivables - Other (2012) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,130.97 Bn 1,099.55 Bn 19.71 Bn
2 Johnson & Johnson 614.97 Bn 533.50 Bn 17.26 Bn
3 AbbVie 505.56 Bn 478.67 Bn 12.70 Bn
4 Merck 366.86 Bn 321.23 Bn 12.21 Bn
5 Novartis Ag 297.80 Bn 261.79 Bn 11.24 Bn
6 Astrazeneca 261.62 Bn 235.31 Bn 12.86 Bn
7 Amgen 235.78 Bn 191.18 Bn 7.24 Bn
8 Gilead Sciences 189.91 Bn 164.11 Bn 6.22 Bn
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn
10 CytoDyn 328.13 Mn 286.31 Mn -
Historic Data

Historic Data

Download Data
DateValue
Aug 31, 2012 250,000.00
API Access

CytoDyn Receivables - Other API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=receivables-other&ticker=CYDY&period=max&api_key=YOUR_API_KEY